PENNSYLVANIA PACE PRESCRIPTION DRUG PRICE REBATES
Executive Summary
PENNSYLVANIA PACE PRESCRIPTION DRUG PRICE REBATES would be based on best prices indexed to July 1, 1990, under an amendment the state intends to propose on April 23. If enacted with such an amendment, state legislation now under consideration would require drug manufacturers participating in the Pharmaceutical Assistance Contract for the Elderly (PACE) program to pay the state rebates sufficient to reduce its costs to best prices available on July 1, 1990, with an allowance for inflation. The amendment would distinguish the PACE bill from federal law, under which an inflation index is tied to average manufacturers prices (AMPs) available to the retail trade rather than to the best prices available to favored customers, such as large nonprofit hospitals. The state bill (HB 495) was introduced in February ("The Pink Sheet" Feb. 18, p. 5) in a form identical to federal rebate legislation enacted last autumn for Medicaid. At a hearing on the state bill ("The Pink Sheet" April 8, T&G-4), federal Senate Special Committee on Aging staffer John Coster recommended that the state shift the index from AMPs to best prices to maximize rebate revenues. Coster noted that many manufacturers have raised their best prices, which under the federal legislation are free from indexing, to decrease the amount of rebates owed Medicaid. Pharmaceutical industry executives testifying at the hearing urged that the bill be amended to require flat percentage rebates.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth